| 1 | Cancer | Jessica | Mamallapalli | J. Botello; C. Xing | Kava inhibits norepinephrine-induced cAMP production in lung cancer cells | Floor 2, Table 1 | Monday, April 12, 2021 | 8:30am - 10:30am ET |
| 2 | Cancer | Yuma | Ortiz | J. Wilkerson; L. McMahon | Mitragynine reverses paclitaxel chemotherapy-induced peripheral neuropathy | Floor 2, Table 2 | Monday, April 12, 2021 | 8:30am - 10:30am ET |
| 4 | Cancer | Richard | Marrero | A. Elsayed; N. Nguyen; X. Cao; H. Wu; S. Raimondi; R. Riberio; J. Rubnitz; S. Pounds; J. Lamba | Association of genetic polymorphisms in SAMHD1 gene on clinical outcomes in AML | Floor 2, Table 4 | Monday, April 12, 2021 | 8:30am - 10:30am ET |
| 5 | Cancer | Zachary | Rabinowitz | L. Cui | Development of bioavailable substrate-based probes for PARP-1 | Floor 2, Table 5 | Monday, April 12, 2021 | 8:30am - 10:30am ET |
| 6 | Cancer | Sebastian | Jugl | C. Chang; Y. Wang; J. Brown | Real-world patterns of CDK4/6 inhibitor associated interstitial-lung disease | Floor 2, Table 6 | Monday, April 12, 2021 | 8:30am - 10:30am ET |
| 7 | Cancer | Jing | Pei | D. Lyu; Y. Xiao; G. Zheng; D. Zhou | Explore the potential of piperlongumine (PL) as a new E3 ligase ligand | Floor 2, Table 7 | Monday, April 12, 2021 | 8:30am - 10:30am ET |
| 9 | Cancer | Kelton | Schleyer | J. Liu; Z. Wang; B. Fetrow; P. Fatland; A. Rollins; V. Wajsbrot; H. Guo; L. Cui | Expanding the toolkit of small molecule imaging probes for heparanase | Floor 2, Table 9 | Monday, April 12, 2021 | 8:30am - 10:30am ET |
| 10 | Pain & Addiction | Noor | Nahid | E. Cicali; C. McDonough; Y. Gong; J. Johnson | Impact of CYP2D6 inhibitors on opioid therapy in patients with pain | Floor 3, Table 1 | Monday, April 12, 2021 | 9:30am - 12:30pm ET |
| 11 | Pain & Addiction | Ching-Yuan | Chang | J. Hincapie-Castillo; D. Wilson; W. Lo-Ciganic | Trends and characteristics of concurrent opioid use with high-risk medications | Floor 3, Table 2 | Monday, April 12, 2021 | 9:30am - 12:30pm ET |
| 12 | Pain & Addiction | Mallory | Burns | S. Intagliata; R. Rogers; S. Kamble; J. Cano; T. Kawesa; B. Avery; L. Toll; C. McCurdy | SAR and SMR investigation of thiol-Linker containing Sigma Receptor ligands | Floor 3, Table 3 | Monday, April 12, 2021 | 9:30am - 12:30pm ET |
| 13 | Pain & Addiction | Julio | Zuarth-Gonzalez | A. Patel; R. Patel; M. Patel; L. Gamez-Jimenez; N. Ho; F. Leon; M. Mottinelli; C. McCurdy; L. McMahon; T. Hiranita. | Mitragynine attenuates the development of morphine tolerance and withdrawal | Floor 3, Table 4 | Monday, April 12, 2021 | 9:30am - 12:30pm ET |
| 14 | Pain & Addiction | Bo | Sortman | C. Gobin; B. Warren | Cocaine seeking is mediated by Fos-expressing ensembles formed during acquisition | Floor 3, Table 5 | Monday, April 12, 2021 | 9:30am - 12:30pm ET |
| 15 | Pain & Addiction | Ariana | Brice-Tutt | S. Eans; D. Yakovlev; T. Yakovleva; J. Aldrich; J. McLaughlin | Development of a kappa opioid receptor antagonist to treat opioid use disorder | Floor 3, Table 6 | Monday, April 12, 2021 | 9:30am - 12:30pm ET |
| 16 | Pain & Addiction | Amy | Alleyne | L. Wilson; S. Harden; C. McCurdy; C. Frazier; J. McLaughlin | Sigma-1 ligands modulate methamphetamine sensitization and reward circuitry | Floor 3, Table 7 | Monday, April 12, 2021 | 9:30am - 12:30pm ET |
| 17 | Pain & Addiction | Erin | Berthold | S. Kamble; M. Kuntz; S. Kanumuri; T. King; B; Shaikoski; A; Sharma; C. McCurdy | Comparative pharmockinetic study of cannabidiol formulations | Floor 3, Table 8 | Monday, April 12, 2021 | 9:30am - 12:30pm ET |
| 18 | Pain & Addiction | Ariana | Figueroa | P. Zhang; A. Alleyne; S. Eans; T. Cirino; J. McLaughlin; S. Stevens; B. Liu | Effect of peripheral inflammation on microglial phenotypes: impact of SPP1 KO | Floor 3, Table 9 | Monday, April 12, 2021 | 9:30am - 12:30pm ET |
| 19 | Pain & Addiction | Todd | Sahagian | J. Thinschmidt; S. Harden; E. Krause; J. Peris, C. Frazier | Oxytocinergic modulation of VTA --> NAc reward circuitry | Floor 3, Table 10 | Monday, April 12, 2021 | 9:30am - 12:30pm ET |
| 20 | Pain & Addiction | Morgan | Crowley | S. Obeng; V. Pallares; F. Leon; L. Gamez-Jimenez; T. Hiranita; L. McMahon; C. McCurdy | Pharmacological comparison of a synthetic analog of a mitragyna speciosa alkaloid | Floor 3, Table 11 | Monday, April 12, 2021 | 9:30am - 12:30pm ET |
| 21 | Pain & Addiction | Yun | Shen | A. Goodin; J. Brown | Prescribing measures and medical marijuana physician authorization status in FL | Floor 3, Table 12 | Monday, April 12, 2021 | 9:30am - 12:30pm ET |
| 22 | Chronic Diseases | Yahan | Zhang | J. Bian; J. Huo; S. Yang; Y. Guo; H. Shao | Downstream costs and healthcare utilization of LDCT screening in ADRD patients | Floor 4, Table 1 | Monday, April 12, 2021 | 12:30pm - 3:00pm ET |
| 23 | Chronic Diseases | Piaopiao | Li | R. Patel; S. Vouri; L. Shi; V. Fonseca; H. Shao | The diminishing cost-effectiveness of newer glucose-lowering drug classes in U.S. | Floor 4, Table 2 | Monday, April 12, 2021 | 12:30pm - 3:00pm ET |
| 24 | Chronic Diseases | Zachary | Greenberg | M. He | Deep learning directed functionalization of exosomes for precision therapeutics | Floor 4, Table 3 | Monday, April 12, 2021 | 12:30pm - 3:00pm ET |
| 25 | Chronic Diseases | Earl | Morris | N. Tokatly; C. Tortor; S. Vouri | Statin initiation for secondary prevention of ASCVD events in older adults | Floor 4, Table 4 | Monday, April 12, 2021 | 12:30pm - 3:00pm ET |
| 26 | Chronic Diseases | Shaimaa | Elbalkiny | R. Frye; Y.Gong | Association of CES1 and FXR SNPs with susceptibility to NAFLD and NASH in the UKB | Floor 4, Table 5 | Monday, April 12, 2021 | 12:30pm - 3:00pm ET |
| 27 | Chronic Diseases | Golnoosh | Alipour-Haris | L. Galiano; C. Hernandez; C.A. Leeflang; Z. Shultz; T. Muir; J. Brown | Medication regimen complexity and deprescribing in Alzheimer and related dementia | Floor 4, Table 6 | Monday, April 12, 2021 | 12:30pm - 3:00pm ET |
| 28 | Chronic Diseases | Jesus | Penaloza Aponte | S. Eikenberry; J. Smith; A. de Kloet; E. Krause; K. Scott | Automated pipeline for analysis of social behavior and neuronal activity in mice | Floor 4, Table 7 | Monday, April 12, 2021 | 12:30pm - 3:00pm ET |
| 29 | Chronic Diseases | Christelle | Lteif | R. Sharma; J. Duarte | Mirabegron improves RVSP in a pre-clinical model of PH-HFpEF | Floor 4, Table 8 | Monday, April 12, 2021 | 12:30pm - 3:00pm ET |
| 30 | Chronic Diseases | Aimalohi | Okpeku | A. Goodin | Impact of mental health on readmissions among persons living with HIV | Floor 4, Table 9 | Monday, April 12, 2021 | 12:30pm - 3:00pm ET |
| 31 | Chronic Diseases | Shu | Huang | W. Lo-Ciganic; H. Shao | Cost-effectiveness of intensive vs. moderate hypertension treatment in US adults | Floor 4, Table 10 | Monday, April 12, 2021 | 12:30pm - 3:00pm ET |
| 32 | Chronic Diseases | Mingxin | Yang | M. Yang; G. de Lartigue | The role of nutrient-sensing hippocampal neurons in feeding | Floor 4, Table 11 | Monday, April 12, 2021 | 12:30pm - 3:00pm ET |
| 33 | Chronic Diseases | Jordan | Howard | T. Sahagian; W. Sheng; S. Harden; J. Thinschmidt; C. Frazier | Cellular neurophysiology of OTR activation in the rat ventral subiculum | Floor 4, Table 12 | Monday, April 12, 2021 | 12:30pm - 3:00pm ET |
| 34 | Infectious Diseases | Elham | Amini | S. Berger; J. Bulitta; G. Hochhaus | Can pharmacokinetics assess the local bioequivalence of suspension nasal sprays? | Floor 5, Table 1 | Monday, April 12, 2021 | 1:30pm - 4:00pm ET |
| 35 | Infectious Diseases | Ikenna | Unigwe | S. Yang; H. Song; W. Lo-Ciganic; R. Cook; H. Park | Trends of STD in the United States ambulatory care clinics from 2005-2016 | Floor 5, Table 2 | Monday, April 12, 2021 | 1:30pm - 4:00pm ET |
| 36 | Infectious Diseases | Jieqiang | Zhou | Y. Lang; T. Kim; X. Tao; A. Sayed; E. Shin; C. Werkman; A. Louie; G. Drusano; C. Landersdorfer; J. Bulitta | Characterizing thermal stability of ?-lactam antibiotics in broth, agar and water | Floor 5, Table 3 | Monday, April 12, 2021 | 1:30pm - 4:00pm ET |
| 37 | Infectious Diseases | Dake | Liu | T. Wanniarachchi; S. Bruner; Y. Ding | Novel metabolism of 5-nitroimidazole antibiotics by a pathogen nitroreductase | Floor 5, Table 4 | Monday, April 12, 2021 | 1:30pm - 4:00pm ET |
| 38 | Infectious Diseases | Chaejin | Kim | J. Barrett; R. Lowenthal; S. Tanimoto; S. Schmidt; V. Vozmediano | Development of a physiologically based nasal absorption model and its application | Floor 5, Table 5 | Monday, April 12, 2021 | 1:30pm - 4:00pm ET |
| 39 | Infectious Diseases | Evelyn | Franco | K. Hanrahan; A. Brown | Favipiravir inhibits Zika virus in HeLa cells by modulating viral infectivity | Floor 5, Table 6 | Monday, April 12, 2021 | 1:30pm - 4:00pm ET |
| 40 | Infectious Diseases | Lobna | Elsadek | J. Matthews; S. Nishimura; T. Nakatani; A. Ito; T. Gu; D. Luo; L. Salvador-Reyes; V. Paul; H. Kakeya; H. Luesch | Genomic and targeted approaches unveil targets of an antifungal natural product | Floor 5, Table 7 | Monday, April 12, 2021 | 1:30pm - 4:00pm ET |
| 41 | Infectious Diseases | Eunjeong | Shin | N. Shah; J. Oyer; A. Sayed; D. Sutaria; X. Tao; Y. Lang; J. Zhou; C. Werkman; A. Copik; J. Bulitta | Synergistic killing of Klebsiella pneumoniae by double ?-lactams combinations | Floor 5, Table 8 | Monday, April 12, 2021 | 1:30pm - 4:00pm ET |
| 42 | Infectious Diseases | Simon | Berger | E. Amini; J. Bulitta; G. Hochhaus | Alternative regulatory pathway for generic approval of nasal suspensions | Floor 5, Table 9 | Monday, April 12, 2021 | 1:30pm - 4:00pm ET |
| 43 | Infectious Diseases | Carolin | Werkman | N. Shah; D. Lucas; J. Oyer; M. Megroz; A. Sayed; B. Moya; A. Wright; D. Sutaria; X. Tao; Y. Lang; J. Zhou; E. Shin; R. Jiminez-Nieves; K. Cadet; A. Copik; J. Boyce; J. Bulitta | Synergistic killing of acinetobacter baumannii via penicillin-binding proteins | Floor 5, Table 10 | Monday, April 12, 2021 | 1:30pm - 4:00pm ET |
| 44 | Infectious Diseases | Garret | Rubin | Y. Zhang; K. Patel; M. Guo; A. Ishee; S. Bruner; Y. Ding | New enzymology in the biosynthesis of anti-protease tricyclic peptides | Floor 5, Table 11 | Monday, April 12, 2021 | 1:30pm - 4:00pm ET |
| 45 | Drug Metabolism, Interactions, & Outcomes | Dawei | Guan | H. Shao | Trends of insulin price across different health insurance plans | Floor 6, Table 1 | Monday, April 12, 2021 | 2:30pm - 5:00pm ET |
| 46 | Drug Metabolism, Interactions, & Outcomes | Shailina | Keshwani | I. Grande; M. Maguire; A. Goodin; S. Vouri; J. Hincapie-Castillo | Trends in utilization of prescription NSAIDs following Floridas HB21 law | Floor 6, Table 2 | Monday, April 12, 2021 | 2:30pm - 5:00pm ET |
| 47 | Drug Metabolism, Interactions, & Outcomes | Raj | Desai | S. Smith | Accuracy of developing new user cohorts using electronic health records data | Floor 6, Table 3 | Monday, April 12, 2021 | 2:30pm - 5:00pm ET |
| 48 | Drug Metabolism, Interactions, & Outcomes | Seonkyeong | Yang | A. Lipe; M. Boren; J. Hincapie-Castillo; J. Brown; J. Guo; H. Park; C. Chang; D. Wilson; L. Adkins; W. Lo-Ciganic | Trends in the management of headache in US emergency departments: 2007-2018 | Floor 6, Table 4 | Monday, April 12, 2021 | 2:30pm - 5:00pm ET |
| 49 | Drug Metabolism, Interactions, & Outcomes | Amir | Sarayani | J. Brown; S. Schmidt; A.. Winterstein | Does CYP3A4 induction by topiramate undermine oral contraceptive effectiveness? | Floor 6, Table 5 | Monday, April 12, 2021 | 2:30pm - 5:00pm ET |
| 50 | Drug Metabolism, Interactions, & Outcomes | Yuli | Qian | J. Markowitz | Pharmacokinetic interactions between methylphenidate and cannabinoids | Floor 6, Table 6 | Monday, April 12, 2021 | 2:30pm - 5:00pm ET |
| 51 | Drug Metabolism, Interactions, & Outcomes | Brianna | Costales | R. Matthews; J. Brown; A. Goodin | A pharmacovigilance analysis of restless legs syndrome treatments and suicidality | Floor 6, Table 7 | Monday, April 12, 2021 | 2:30pm - 5:00pm ET |
| 52 | Drug Metabolism, Interactions, & Outcomes | Brandon | Klee | P. Melchert; Y. Qian; C. Galloway; J. Markowitz | Investigating the pharmacogenomics of ADHD in youth treated with methylphendate | Floor 6, Table 8 | Monday, April 12, 2021 | 2:30pm - 5:00pm ET |
| 53 | Drug Metabolism, Interactions, & Outcomes | Phuong | Tran | P. Antonelli; A. Winterstein | Quinolone ear drops linked to tendinopathy and tendon rupture | Floor 6, Table 9 | Monday, April 12, 2021 | 2:30pm - 5:00pm ET |
| 54 | Drug Metabolism, Interactions, & Outcomes | Nicole | Smolinski | P. Antonelli; A. Winterstein | Trends in the diagnosis and treatment of pediatric acute otitis media | Floor 6, Table 10 | Monday, April 12, 2021 | 2:30pm - 5:00pm ET |
| 55 | Drug Metabolism, Interactions, & Outcomes | Brian | Cicali | K. Lingineni; R. Cristofoletti; T. Wendl; J. Hoechel; H. Wiesinger; A. Chaturvedula; V. Vozmediano; S. Schmidt | Levonorgestrel DDI studies in healthy and obese women using PBPK modeling | Floor 6, Table 11 | Monday, April 12, 2021 | 2:30pm - 5:00pm ET |
| 8 | Cancer | Nam | Nguyen | H. Wu; J. Ping; J. Rubnitz; S. Pounds; J. Lamba | Leukemic cell proteomic profiling in pediatric AML: a pilot study | Floor 6, Table 12 | Monday, April 12, 2021 | 2:30pm - 5:00pm ET |
| 70 | PharmD: Group A | Julia | Lessing | J. Boyle-Taylor; L. Dupree; A. Casapao | Competent vs. developing abstract skills: does past writing experience matter? | Floor 2, Table 1 | Tuesday, April 13, 2021 | 8:00am - 9:30am ET |
| 71 | PharmD: Group A | Kylie | Paul | K. O'Mara; D. de la Cruz; K. Kisilewicz | Comparative outcomes of Intralipid to SMOFlipid in extremely premature neonates | Floor 2, Table 2 | Tuesday, April 13, 2021 | 8:00am - 9:30am ET |
| 72 | PharmD: Group A | Savine | Hernandez | V. Venugopalan; K. DeSear; B. Santevecchi; J. Ashton; K. Cherabuddi; M. Alshaer; C. Peloquin; A. Casapao | Optimizing cefazolin dosing in the treatment of MSSA bacteremia | Floor 2, Table 3 | Tuesday, April 13, 2021 | 8:00am - 9:30am ET |
| 73 | PharmD: Group A | Erik | Kienegger | B. Gonzalez; S. Berger; E. Amini; J. Bulitta; G. Hochhaus | Systematic evaluation of the ex-throat plume properties of MDI formulations | Floor 2, Table 4 | Tuesday, April 13, 2021 | 8:00am - 9:30am ET |
| 74 | PharmD: Group A | Andrew | Garcia | T. Edminster; I. Molina; M. Muehlbauer | Immunomodulator therapy as salvage therapy to failing biologics in IBD patients | Floor 2, Table 5 | Tuesday, April 13, 2021 | 8:00am - 9:30am ET |
| 75 | PharmD: Group A | Nazifa | Kadery | A. Ignacio; A. Tenpas; C. DeRemer | Evaluating the use of SGLT-2 inhibitors on weight change and microalbuminuria | Floor 2, Table 6 | Tuesday, April 13, 2021 | 8:00am - 9:30am ET |
| 76 | PharmD: Group A | Parminder | Kaur | A. Carr; A. El Ghali; P. Kaur; S. Minor; A. Casapao | Early real-world evidence of eravacycline in draconian infections | Floor 2, Table 7 | Tuesday, April 13, 2021 | 8:00am - 9:30am ET |
| 77 | PharmD: Group A | Julie | Al-Bahou | S. Vouri; H. Bhagwandass; I. Valdes; A. Alsuhibani | Changes in overactive bladder medication use before and after bariatric surgery | Floor 2, Table 8 | Tuesday, April 13, 2021 | 8:00am - 9:30am ET |
| 78 | PharmD: Group A | Blake | Bartlett | M. Norris | Literature review of potential CYP2D6 inhibitors and their classifications | Floor 2, Table 9 | Tuesday, April 13, 2021 | 8:00am - 9:30am ET |
| 79 | PharmD: Group A | Matthew | Muschett | J. Brown | Risk factors and costs associated with heart transplant readmissions in the U.S. | Floor 2, Table 10 | Tuesday, April 13, 2021 | 8:00am - 9:30am ET |
| 80 | PharmD: Group A | Megan | Backus | A. Strahorn; S. Matys; A. Yathali; V. Grusauskas | Antidepressant prescribing patterns at a student-run free healthcare clinic | Floor 2, Table 11 | Tuesday, April 13, 2021 | 8:00am - 9:30am ET |
| 81 | PharmD: Group A | Christen | Langley | A. Chizmar; S. Voils; A. Casapao | Perception vs reality: cross-sectional study of the 2020 pharmacy residency match | Floor 2, Table 12 | Tuesday, April 13, 2021 | 8:00am - 9:30am ET |
| 56 | Post-Doc Trainee/Resident | Tengfei | Bian | Y. Wang; J. Botello; Q. Hu; Y. Jiang; A. Zingone; P. Corral; F. Aly; Y. Wu; B. Ryan; L. Jin; C. Xing | NNAL promotes lung cancer progression in an isomer-dependent manner | Floor 3, Table 1 | Tuesday, April 13, 2021 | 8:30am - 11:30am ET |
| 57 | Post-Doc Trainee/Resident | Xiaoshu | Pan | P. Huang; N. Fernandez; Z. Greenberg; H. Staecker; M. He | CRISPR-Exosome nanoassembles for precise genetic correction in hearing loss | Floor 3, Table 2 | Tuesday, April 13, 2021 | 8:30am - 11:30am ET |
| 58 | Post-Doc Trainee/Resident | Dinesh | Thummuri | S. Khan; P. Underwood; X. Zhang; P. Zheng; V. Budamagunta; A. Sobh; A. Tagmount; A. Loguinov; E. Williamson; J. Wiegand; R. Hromas; C. Vulpe; G. Zheng; J. Trevino; D. Zhou. | BCL-XL PROTAC-Gemcitabine combination as a potent therapy for pancreatic cancer | Floor 3, Table 3 | Tuesday, April 13, 2021 | 8:30am - 11:30am ET |
| 59 | Post-Doc Trainee/Resident | Marwa | Tantawy | M. Chekka; T. Garrett; S. Singh; C. Shah; M. Fradley; R. Cornell; R. Baz; N. Waheed; D. DeRemer; L. Yuan; T. Langaee; K. March; C. Pepine; J. Moreb; Y. Gong | Lactate dehydrogenase B associated with carfilzomib relate cardiotoxicity | Floor 3, Table 4 | Tuesday, April 13, 2021 | 8:30am - 11:30am ET |
| 60 | Post-Doc Trainee/Resident | Juan | Morales | J. Podichetty; J. Burton; N. Hanan; M. Thomas; K. Lingineni; P. Lang; S. David; F. Martin; M. Atkinson; M. Haller; K. Romero; I. O'Doherty; S. Schmidt; S. Kim | Quantifying heterogeneity contributing to risk of type 1 diabetes diagnosis | Floor 3, Table 5 | Tuesday, April 13, 2021 | 8:30am - 11:30am ET |
| 61 | Post-Doc Trainee/Resident | Khalid | Elsaafien | M. Kirchner; M. Mohammed; S. Eikenberry; C. West; K. Scott; A. de Kloet; J. Stern; E. Krause | Angiotensin signaling in the paraventricular nucelus elevates blood pressure | Floor 3, Table 6 | Tuesday, April 13, 2021 | 8:30am - 11:30am ET |
| 62 | Post-Doc Trainee/Resident | Vivek | Shastri | A. Elsayed; L. Chauhan; T. Alonzo; Y. Wang; R. Aplenc; B. Hirsch; A. Gamis; S. Meshinchi; J. Lamba | DDR-4-SNP score predicts GO response in AML patients: a pathway-directed analysis | Floor 3, Table 7 | Tuesday, April 13, 2021 | 8:30am - 11:30am ET |
| 63 | Post-Doc Trainee/Resident | Kimberly | Atkinson | K. Vogel Anderson; M. Lo | Pharmacists increase access to diabetes supplies in an outpatient clinic setting | Floor 3, Table 8 | Tuesday, April 13, 2021 | 8:30am - 11:30am ET |
| 64 | Post-Doc Trainee/Resident | Tao | Long | R.Cristofoletti; V. Michaud; P. Dow; J. Turgeon; S. Schmidt | PBPK modeling to assess CYP2D6-mediated DDI on tramadol and metabolite exposures | Floor 3, Table 9 | Tuesday, April 13, 2021 | 8:30am - 11:30am ET |
| 65 | Post-Doc Trainee/Resident | Michelle | Pressly | S. Schmidt | Agent-based approach to understanding bone remodeling in osteoporosis | Floor 3, Table 10 | Tuesday, April 13, 2021 | 8:30am - 11:30am ET |
| 66 | Post-Doc Trainee/Resident | Laura | Hanold | A. Cheek; J. Aldrich | The peptide [D-Trp]CJ-15,208 regulates proteins in the c-Myc degradation pathway | Floor 3, Table 11 | Tuesday, April 13, 2021 | 8:30am - 11:30am ET |
| 67 | Post-Doc Trainee/Resident | Yuzhi | Wang | T. Bian; L. Jin; C. Xing | Nicotine exposure induces resistance to chemotherapy in small cell lung cancer | Floor 3, Table 12 | Tuesday, April 13, 2021 | 8:30am - 11:30am ET |
| 68 | Post-Doc Trainee/Resident | Yinzhi | Lang | J. Zhou; N. Smith; X. Tao; A. Sayed; E. Shin; W. Carolin; R. Cha; B. Tsuji; J. Bulitta | Outer membrane (OM) permeability of six ?-lactams in New Delhi metallo-?-lactamas | Floor 3, Table 13 | Tuesday, April 13, 2021 | 8:30am - 11:30am ET |
| 69 | Post-Doc Trainee/Resident | Hamed | Kianmehr | J. Guo; J. Luo; L. Shi; V. Fonseca; H. Shao | To examine patient characteristics on incident congestive heart failure (CHF) | Floor 3, Table 14 | Tuesday, April 13, 2021 | 8:30am - 11:30am ET |
| 82 | PharmD: Group B | Jisoo | Kim | N. Seligson; B. Duong; K. Blake; K. Cook | Pharmacogenomic medication use in pediatrics patients with sickle cell disease | Floor 4, Table 1 | Tuesday, April 13, 2021 | 9:00am - 10:30am ET |
| 83 | PharmD: Group B | Shivani | Mehta | S. Mehta; E. Elwood; K. Vigal; G. Rosier; R. Rhoden; A. Williams; A. Cobb; P. Williams; F. Kaba; J. Alonso; E. Eddy; R. Copper-DeHoff | Genetic testing to understand and address renal disease disparities across the US | Floor 4, Table 2 | Tuesday, April 13, 2021 | 9:00am - 10:30am ET |
| 84 | PharmD: Group B | Natasha | Emanuel | T. Larkin; A. Elsayed; R. Rafiee; B. Greer; B. Horn; J. Lamba | Identification of SNPs to optimize the treatment of acute childhood leukemia | Floor 4, Table 3 | Tuesday, April 13, 2021 | 9:00am - 10:30am ET |
| 85 | PharmD: Group B | Mahnoor | Izhar | P. Molina; M. Thomas; E. Quesinberry; N. Seligson | Secondary genomic variants across fusion-driven sarcomas | Floor 4, Table 4 | Tuesday, April 13, 2021 | 9:00am - 10:30am ET |
| 86 | PharmD: Group B | Monica | Bennett | S. Millis; D. Jin; N. Grosenbacher; C. Stets; J. Elvin; W. Miles; J. Hays; J. Chen; N. Seligson | Identifying predictors of loss of heterozygosity in leiomyosarcoma | Floor 4, Table 5 | Tuesday, April 13, 2021 | 9:00am - 10:30am ET |
| 87 | PharmD: Group B | Wendy | Caba Piloto | E. Mougey; C. Gutiérrez-Junquera; S. Fernández-Fernández; M. Luz Cilleruelo; A. Rayo; B. Borrell; E. Román; C. González-Lois; M. Chao; H. Al-Atrash; J. Franciosi | TSLP/WDR36 variant associates with PPIREE | Floor 4, Table 6 | Tuesday, April 13, 2021 | 9:00am - 10:30am ET |
| 88 | PharmD: Group B | Erin | Shepard | Y. Coll; S. Millis; J. Hays; J. Chen; N. Seligson | Alterations in histone H3 modifying henes in synovial sarcoma | Floor 4, Table 7 | Tuesday, April 13, 2021 | 9:00am - 10:30am ET |
| 89 | PharmD: Group B | Charles | Verduzco | C. Lawrence; A. Phillips; T. Tran; D. Wang | Regulatory polymorphisms in CYP2D6 and their clinical implications | Floor 4, Table 8 | Tuesday, April 13, 2021 | 9:00am - 10:30am ET |
| 90 | PharmD: Group B | Breonna | Harrison | R. Callender; J. Lamba; C. Ramos | Impact of gene associated methotrexate toxicity in acute lymphoblastic leukemia | Floor 4, Table 9 | Tuesday, April 13, 2021 | 9:00am - 10:30am ET |
| 91 | PharmD: Group B | Bradley | Hall | N. Desai; A. Elchynski; Y. Marks; D. D'Silva; K. Nguyen | Utilizing a HCI approach to evaluate the design of current PGx-CDS | Floor 4, Table 10 | Tuesday, April 13, 2021 | 9:00am - 10:30am ET |
| 92 | PharmD: Group B | Connie | Mei | Z. Gruen; L. Dumeny; L. Cavallari | Pharmacogenomics implementation in the arthroplasty setting | Floor 4, Table 11 | Tuesday, April 13, 2021 | 9:00am - 10:30am ET |
| 93 | PharmD: Group B | Orniel | Caban | E. Alini; R. Glaubrecht; A. Parchment; N. Seligson | Prevalence of single cell transcriptomic heterogeneity in sarcoma | Floor 4, Table 12 | Tuesday, April 13, 2021 | 9:00am - 10:30am ET |
| 94 | PharmD: Group B | Danielle | Pellett | L. Garayeva; P. Martinez-Quinones; J. Ngo; H. Fellows; J. Duarte | Clinical implementation of preemptive pharmacogenetic testing in the literature | Floor 4, Table 13 | Tuesday, April 13, 2021 | 9:00am - 10:30am ET |
| 95 | PharmD: Group B | Hanh | Tran | L. Becirevic; N. Emanuel; M. Lofy; V. Shastri; J. Lamba | Ara-C SNP score to personalize cytarabine dosing: a retrospective study | Floor 4, Table 14 | Tuesday, April 13, 2021 | 9:00am - 10:30am ET |
| 96 | PharmD: Group B | Melissa | Cuevas | J. Kelly; J. Lamba | Gene associated asparaginase hypersensitivity in pediatric ALL | Floor 4, Table 15 | Tuesday, April 13, 2021 | 9:00am - 10:30am ET |
| 110 | Undergraduate Student | Shelby | Luckey | A. Singh; G. de Lartigue | Bardet-Biedl syndrome 5 gene mutation promotes leptin resistance and obesity | Floor 5, Table 1 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 111 | Undergraduate Student | Isadora | Braga | A. Araujo; G. De Lartigue | Asymmetrical recruitment of vagal motor neurons by vagal sensory neurons | Floor 5, Table 2 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 112 | Undergraduate Student | Katelyn | Rourk | A. Singh; A. Bernier; G. de Lartigue | Can sweetened drinks impair metformins effect on glucose control in obese mice? | Floor 5, Table 3 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 113 | Undergraduate Student | Alberto | Jimenez Ybargollin | G. Zeng; W. Zhao; Z. Chen; X. Li; F. Liang; L. Cui | Epigenetic control of heparanase expression through CRISPR/dCas9 | Floor 5, Table 4 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 114 | Undergraduate Student | Victoria | Pallares | S. Obeng; M. Mottinelli; C. McCurdy; L. McMahon; T. Hiranita | In vitro pharmacological characterization of novel fentanyl analogs | Floor 5, Table 5 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 115 | Undergraduate Student | Gabriel | Leme | I. Braga; A. de Araujo; G. de Lartigue | Differential control of food intake by left and right vagal sensory neurons | Floor 5, Table 6 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 116 | Undergraduate Student | Jane | Hufnagel | S. Obeng; F. Leon; L. Restrepo; L. Gamez-Jimenez; A. Patel; N. Ho; T. Braun; J. Fortner; M. Crowley; V. Pallares; M. Mottinelli; C. Lopera-Londono; C. McCurdy; L. McMahon; T. Hiranita | Comparison of mu-opioid receptor activity of Kratom alkaloid and its metabolite | Floor 5, Table 7 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 97 | PharmD: Group C | Monique | Hook | B. Dragoljevic; E. McKenna; A. Nguyen; D. Valentin; K. Nguyen; K. Wiisanen; L. Cavallari; A. Elchynski; E. Cicali | Evaluation of prescriber responses to TPMT pre-test alerts at UF Health | Floor 6, Table 1 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 98 | PharmD: Group C | Joshua | Bilbrey | Y. Ortiz; J. Felix; L. McMahon; J. Wilkerson | Evaluating effects of terpenoid compounds in mice with chronic neuropathic pain | Floor 6, Table 2 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 99 | PharmD: Group C | Taylor | Easey | J. Hincapie-Castillo; S. Vouri; A. Goodin | Impact of opioid acute pain limitation laws on opioid overdose deaths | Floor 6, Table 3 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 100 | PharmD: Group C | Lismaury | Galiano | C. Hernandez Zengotita; J. Brown; G. Alipour Haris | Review of medication regimen for patients with ADRD in sleep apnea guidelines. | Floor 6, Table 4 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 101 | PharmD: Group C | Maryam | Deravi | T. Tablante; L. Adkins; A. Goodin; J. Hincapie-Castillo | Systematic review of social media data sources for substance use trends | Floor 6, Table 5 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 102 | PharmD: Group C | Sophie | Bennett | E. Altamura; S. Bell; K. Cabrera; B. Zhang; C. Kim; V. Vozmediano | Review of nasal route for systemic and brain delivery: advantages and challenges | Floor 6, Table 6 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 103 | PharmD: Group C | Natalie | Ourhaan | H. Bhagwandass; A. Goodin; J. Hincapie-Castillo | Utilization trends of amphetamine-containing medications following law changes | Floor 6, Table 7 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 104 | PharmD: Group C | Ivanna | Grande | S. Keshwani; J. Hincapie-Castillo | Impact of opioid prescribing limits on NSAID use in state Medicaid programs | Floor 6, Table 8 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 105 | PharmD: Group C | India | Auchey | J. Brown | Cannabis use in pregnancy: a review of the literature | Floor 6, Table 9 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 106 | PharmD: Group C | Avi | Patel | S. Obeng; L Restrepo; L. Gamez-Jimenez; N. Ho; F. León; M. Mottinelli; C. McCurdy; L. McMahon; T. Hiranita | The primary kratom alkaloid mitragynine as an in vivo adrenergic-alpha2 receptor | Floor 6, Table 10 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 107 | PharmD: Group C | Tychell | Branchcomb | Y. Shen; H. Bhagwandass; S. Galvez; I. Grande; J. Lessing; M. Mollanazar; N. Ourhaan; R. Oueini; M. Sasser; I. Valdes; A. Jadubans; J. Hollmann; M. Maguire; S. Usmani; S. Vouri; J. Hincapie-Castillo; L. Adkins; A. Goodin | Chronic opioid therapy: a scoping literature review | Floor 6, Table 11 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 108 | PharmD: Group C | Joyce | Hernandez Maldonado | O. Grundmann | Non-HIV DDI's of artemisinin-based combination therapies in malaria treatment | Floor 6, Table 12 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
| 109 | PharmD: Group C | Caroline | Leeflang | J. Brown; G. Alipour Haris; C. Hernandez Zengotita | Psychiatric medication regimen complexity and eprescribing in ADRD | Floor 6, Table 13 | Tuesday, April 13, 2021 | 10:00 - 11:30am ET |
